Subcutaneous Epcoritamab in Combination with Rituximab plus Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

被引：11

作者：

Falchi, Lorenzo ^{[1
]}

Leslie, Lori A. ^{[2
]}

Belada, David ^{[3
]}

Kopeckova, Katerina ^{[4
]}

Offner, Fritz ^{[5
]}

Brody, Joshua ^{[6
]}

Canales, Miguel ^{[7
]}

Martin Garcia-Sancho, Alejandro ^{[8
]}

Nijland, Marcel ^{[9
,10
]}

Andersson, P-O ^{[11
]}

Awan, Farrukh T. ^{[12
]}

Christensen, Jacob Haaber ^{[13
]}

Drott, Kristina ^{[14
]}

Hellstrom, Mats ^{[15
]}

Lewerin, Catharina ^{[16
]}

Narkhede, Mayur ^{[17
]}

Snauwaert, Sylvia ^{[18
]}

Wahlin, Bjorn E. ^{[19
]}

Rana, Ali ^{[20
]}

Abbas, Aqeel ^{[20
]}

Wang, Liwei ^{[20
]}

Minh Dinh ^{[21
]}

Vermaat, Joost S. P. ^{[22
]}

Abrisqueta, Pau ^{[23
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

[2] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[3] Charles Univ Prague, Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[4] Fak Nemocnice Motole, Prague, Czech Republic

[5] Univ Ziekenhuis Gent, Ghent, Belgium

[6] Icahn Sch Med Mt Sinai, New York, NY USA

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Salamanca, Salamanca, Spain

[9] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[10] Univ Groningen, Groningen, Netherlands

[11] Sodra Alvsborgs Sjukhus, Boras, Sweden

[12] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[13] Odense Univ Hosp, Odense, Denmark

[14] Skane Univ Hosp, Lund, Sweden

[15] Uppsala Univ Hosp, Uppsala, Sweden

[16] Sahlgrens Univ Hosp, Gothenburg, Sweden

[17] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[18] AZ Sint Jan Brugge, Dept Hematol, Brugge, Belgium

[19] Karolinska Inst, Stockholm, Sweden

[20] Genmab, Princeton, NJ USA

[21] AbbVie Inc, N Chicago, IL USA

[22] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands

[23] Hosp Univ Vall dHebron, Barcelona, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158232

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1471 / 1473

页数：3

共 50 条

[1] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
[2] Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Linton, Kim M.
Wahlin, Bjorn
Leepa, Sirpa
Morschhauser, Franck
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BLOOD, 2021, 138
[3] Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results
Linton, Kim M.
Wahlin, Bjorn
Leppa, Sirpa
Morschhauser, Franck
Elliott, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 94 - 94
[5] Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Falchi, Lorenzo
Morschhauser, Franck
Gribben, John G.
Huang, Huiqiang
Minh Dinh
Conlon, Rebekah
Chen, Xiaorong
Elliot, Brian
Seymour, John F.
BLOOD, 2022, 140 : 9338 - 9339
[6] Subcutaneous Epcoritamab with Rituximab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
Falchi, Lorenzo
Abrisqueta, Pau
Nijland, Marcel
Leppa, Sirpa
Hutchings, Martin
Holte, Harald
Merryman, Reid W.
Lugtenburg, Pieternella
de Vos, Sven
Cheah, Chan Y.
Christensen, Jacob Haaber
Arcaini, Luca
Drott, Kristina
Hellstrom, Mats
Leslie, Lori A.
Vitolo, Umberto
Rana, Ali
Abbas, Aqeel
Wang, Liwei
Minh Dinh
Belada, David
BLOOD, 2022, 140 : 1464 - 1466
[7] Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update
Lorenzo, Falchi
Sirpa, Leppa
Wahlin, Bjorn E.
Marcel, Nijland
Christensen, Jacob H.
De, Vos Sven
Harald, Holte
Linton, Kim M.
Aqeel, Abbas
Wang Liwei
Minh, Dinh
Brian, Elliott
David, Belada
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S31
[8] CURRENT EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) PERCEPTIONS FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Levine, E.
Gentile, D.
Swain, R.
Bone, R. N.
Jennings-Zhang, L.
Jeune-Smith, Y.
Feinberg, B.
VALUE IN HEALTH, 2024, 27 (12) : S342 - S342
[9] EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.
Linton, Kim M.
Thompson, Philip
Luminari, Stefano
Casulo, Carla
Patah, Poliana
Zeng, Lingmin
Mei, J. P.
Dixit, Neha
Hoehn, Daniela
Bachy, Emmanuel
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
Falchi, Lorenzo
Morschhauser, Franck
Linton, Kim
Huang, Huiqiang
Galderisi, Faith
Quadri, Syed
Zeng, Lingmin
Hoehn, Daniela
Seymour, John F.
BLOOD, 2023, 142

← 1 2 3 4 5 →